Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Journal of Korean Gerontological Nursing ; 24(4):441-453, 2022.
Article in Korean | Scopus | ID: covidwho-2204256

ABSTRACT

Purpose: The purpose of this study was to describe and understand the meaning and essence of care experienced by long-term-care-hospital nurses during the COVID-19 pandemic. Methods: This study is a phenomenological study by Colaizzi (1978) to understand and identify the meaning and essence of long-term-care-hospital nurses' experiences after the COVID-19 outbreak. Data collection was conducted from April to June 2021 for 10 nurses working at a long-term-care hospital. Interviews were conducted face-to-face or non-face-to-face. The face-to-face interviews were conducted in a space following COVID-19-mandated quarantine rules. Results: Seven theme clusters and 24 themes emerged: chaos experienced during the early stage of the pandemic, lack of a standardized care protocol hindering care delivery in long-term-care hospitals, sympathizing with the sorrows of patients and their families, taking the burdensome task of COVID-19 infection control as a nurse, COVID-19 vaccine-related anxiety, anger at the reality of long-term-care hospitals and the stigmatizing society, and hope for recovery from the disaster caused by COVID-19. Conclusion: This study will be helpful in establishing long-term-care policies and systems that will help improve the ability of long-term-care hospitals to cope with a pandemic in the post-COVID-19 era. © 2022 Korean Gerontological Nursing Society.

2.
Annals of Oncology ; 33(Supplement 9):S1561-S1562, 2022.
Article in English | EMBASE | ID: covidwho-2176298

ABSTRACT

Background: Treatment (tx) options are limited for pts with EGFR-mutated (mut) mNSCLC who experience disease progression following EGFR TKIs. CheckMate 722 (NCT02864251) is a randomized, open-label, phase 3 study of NIVO + chemo vs chemo in pts with EGFR-mut mNSCLC after progression on EGFR TKIs. Method(s): Pts with EGFR-mut mNSCLC (including uncommon mutations) with disease progression on 1 or 2 prior lines of EGFR TKI tx (including 1st or 2nd generation TKI for those with no T790M mutation and/or osimertinib regardless of T790M mutation) were stratified by tumor PD-L1, presence of brain metastases, smoking history, and prior osimertinib. Pts were randomized 1:1 to receive NIVO 360 mg Q3W + chemo (platinum + pemetrexed) Q3W or chemo for <= 4 cycles;pts without progression received NIVO + pemetrexed or pemetrexed, respectively, until disease progression, unacceptable toxicity or <= 2 y for NIVO. Primary endpoint: PFS. Secondary endpoints: OS, ORR, DOR, and 9- and 12-mo PFS rates. Result(s): In all, 294 pts were randomized;baseline characteristics were well balanced between treatment arms. At final analysis (minimum follow-up: 18.2 mo), there was no statistically significant improvement in PFS with NIVO + chemo vs chemo (HR [95% CI]: 0.75 [0.56-1.00];P = 0.053). No difference in PFS was seen between treatment arms across most subgroups except in pts with sensitizing EGFR mutations (n = 269) and 1 prior line of EGFR TKI tx (n = 248);HR (95% CI) was 0.72 (0.54-0.97) for both. Other efficacy results are presented (Table). Grade 3-4 treatment-related AEs occurred in 45% (NIVO + chemo) vs 29% (chemo) of pts. [Formula presented] Conclusion(s): NIVO + chemo did not show statistically significant improvement in PFS in pts with EGFR-mut mNSCLC after progression on EGFR TKIs;however, a trend of benefit was seen in pts with sensitizing EGFR mutations and in those with 1 prior line of EGFR TKI tx. No new safety signals were identified. Clinical trial identification: NCT02864251. Editorial acknowledgement: All authors contributed to and approved the ;writing and editorial assistance were provided by Thai Cao, MS, of Envision Pharma Group, funded by Bristol Myers Squibb. Legal entity responsible for the study: Bristol Myers Squibb (Princeton, NJ). Funding(s): Bristol Myers Squibb (Princeton, NJ) and Ono Pharmaceutical Company Ltd. (Osaka, Japan). Disclosure: T.S.K. Mok: Financial Interests, Personal, Invited Speaker: AbbVie, ACEA Pharma, Alpha Biopharma, Amgen, Amoy Diagnostics, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Daiichi Sankyo, Fishawack Facilitate, InMed Medical Communication, Lunit USA, Inc., Merck Serono, MSD, Roche, MD Health, Medscape/WebMD, PeerVoice, Permanyer SL, Prime Oncology, Research to Practice, Touch Medical Media, Sanofi-Aventis, Takeda, PER, Daz Group, Janssen Pharmaceutical NV, Jiahui Holdings Co., LiangYiHui Healthcare, Lucence Health Inc., Merck Pharmaceuticals HK Ltd, MiRXES, Novartis, OrigiMed Co. Ltd., Pfizer, Shanghai BeBirds Translation & Consulting Co., Ltd., Taiho Pharmaceutical Co., Ltd, AstraZeneca;Financial Interests, Personal, Advisory Board: AbbVie, ACEA Pharma, Alpha Biopharma, Amgen, Amoy Diagnostics, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Blueprint Medicines, Berry Oncology, CStone Pharma, Daiichi Sankyo, Fishawack Facilitate, Eisai, Gritstone Oncology, Guardant Health, G1 Therapeutics, Hengrui, Ignyta, IQVIA, Incyte Corporation, Inivata, Janssen, Loxo Oncology, Qiming Dev., Lunit USA, Inc., Merck Serono, MSD, Roche, Mirati Therapeutics, MoreHealth, Novartis, OrigiMed, Puma Tech., Sanofi-Aventis, Takeda, Virtus Medical, Yuhan, Curio Science, Bayer Healthcare Pharmaceuticals Ltd., Covidien LP, C4 Therapeutics, Cirina Ltd., Da Volterrra, F. Hoffmann-La Roche Ltd / Genentech, Gilead Sciences, Lucence Health Inc., Medscape LLC / WebMD, MiRXES, OSE Immunotherapeutics, Pfizer, SFJ Pharmaceutical Ltd., Synergy Research, Tigermed, Vertex Pharmaceuticals, Berry Oncology, D3 Bio Ltd., Lakeshore Biotech;Financial In erests, Personal, Invited Speaker, Former known as Hutchison Chi-Med: HutchMed;Financial Interests, Personal, Officer, Chairman: ACT Genomics-Sanomics Group;Financial Interests, Personal, Stocks/Shares: Sanomics Ltd., Biolidics Ltd., Aurora Tele-Oncology, AstraZeneca;Financial Interests, Personal, Stocks/Shares, Former known as Hutchison Chi-Med: HutchMed;Financial Interests, Institutional, Funding, For clinical trials performed at CUHK: AstraZeneca, BMS, Merck Serono, MSD, Novartis, Pfizer, Roche, SFJ Pharmaceuticals, XCovery, Takeda, G1 Therapeutics, Clovis Oncology;Non-Financial Interests, Personal, Advisory Role: geneDecode;Non-Financial Interests, Personal, Other, Invited Speaker: AstraZeneca, Aurora Tele-Oncology, Lunit USA, Inc., Sanomics Ltd.;Non-Financial Interests, Personal, Leadership Role, Term ended on 30 June 2022: American Society of Clinical Oncology (ASCO);Non-Financial Interests, Personal, Leadership Role: Asian Thoracic Oncology Research Group (ATORG), Chinese Lung Cancer Research Foundation Limited (CLCRF), Hong Kong Cancer Fund (HKCF), Hong Kong Cancer Therapy Society (HKCTS), St. Stephen's College & Prep. School (Hong Kong);Non-Financial Interests, Personal, Leadership Role, Term ended: Chinese Society of Clinical Oncology (CSCO);Non-Financial Interests, Personal, Leadership Role, Term ended on 30 April 2019: International Association for the Study of Lung Cancer (IASLC). K. Nakagawa: Financial Interests, Personal, Invited Speaker: Ono Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Amgen Inc., Nippon Kayaku Co., Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., MSD K.K., Pfizer Japan Inc., Nippon Boehringer Ingelheim Co., Ltd., Taiho Pharmaceutical Co.,Ltd., Bayer Yakuhin, Ltd., CMIC ShiftZero K.K., Life Technologies Japan Ltd., Neo Communication, Merck Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., 3H Clinical Trial Inc., Care Net, Inc., Medical Review Co., Ltd., Medical Mobile Communications co., Ltd, YODOSHA CO., LTD., Nikkei Business Publications, Inc., Japan Clinical Research Operations, CMIC Co., Ltd., Novartis Pharma K.K., TAIYO Pharma Co., Ltd.;Financial Interests, Personal, Advisory Board: Ono Pharmaceutical Co.,Ltd., Eli Lilly Japan K.K.;Financial Interests, Institutional, Other, patents sales fee: Daiichi Sankyo Co., Ltd.;Financial Interests, Institutional, Research Grant: PAREXEL International Corp., PRA HEALTHSCIENCES, EPS Corporation., Kissei Pharmaceutical Co., Ltd., EPS International Co.,Ltd,., Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co.,Ltd., MSD K.K., Ono Pharmaceutical Co.,Ltd., PPD-SNBL K.K, SymBio Pharmaceuticals Limited., IQVIA Services JAPAN K.K., SYNEOS HEALTH CLINICAL K.K., Nippon Kayaku Co.,Ltd., EP-CRSU Co., Ltd., Mebix, Inc., Bristol Myers Squibb K.K., Janssen Pharmaceutical K.K., Eisai Co., Ltd., AstraZeneca K.K., Mochida Pharmaceutical Co., Ltd., Covance Japan Inc., Japan Clinical Research Operations, Takeda Pharmaceutical Co.,Ltd., GlaxoSmithKline K.K., Sanofi K.K., Chugai Pharmaceutical Co.,Ltd., Nippon Boehringer Ingelheim Co.,Ltd., Sysmex Corporation, Medical Reserch Support, Eli Lilly Japan K.K., Amgen Inc., Novartis Pharma K.K., Novartis Pharma K.K., SRL, Inc. K. Park: Financial Interests, Personal, Advisory Board: JNJ, Astra Zeneca, Daiichi Sankyo, BMS, Takeda;Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim;Financial Interests, Personal, Other, DMC member: BeiGene, Incyte;Financial Interests, Personal, Other, Advisor/Consultant: Genius, IMBdx;Financial Interests, Institutional, Research Grant: AstraZeneca, MSD. Y. Ohe: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai, ONO, BMS, Eli Lilly, Boehringer Ingelheim, Takeda, MSD, Novartis;Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Celltrion, Amgen, Nippon Kayaku, Takeda, Pfizer, ONO, Janssen, AnHeart Therapeutics Inc;Financial Interests, Institutional, Invited Speaker: AstraZeneca, Eli Lilly, Janssen, Amgen;Financial Interests, Personal and Institutional, Invited Speaker: Takeda, ONO;Non-Financ al Interests, Personal, Leadership Role: JSMO, JLCS, JCOG;Non-Financial Interests, Personal, Member: ASCO. N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi;Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer, Novartis, Sanofi, AbbVie, Amgen, Lilly, Grunenthal, Takeda, Owkin;Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen;Financial Interests, Institutional, Funding: BMS;Non-Financial Interests, Personal, Officer, International Thymic malignancy interest group, president: ITMIG;Other, Personal, Other, Family member is an employee: AstraZeneca. Y. Wu: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Hengrui, Merk, MSD, Pfizer, Roche, Sanofi, AstraZeneca, Boehringer Ingelheim, BMS, Hengrui, Merk, MSD, Pfizer, Roche, Sanofi, Yunhan, Eli Lilly;Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Takeda;Non-Financial Interests, Personal, Leadership Role: Chinese Thoracic Oncology Group (CTONG);Non-Financial Interests, Personal, Other, WCLC 2020 Conference Chair: IASLC;Non-Financial Interests, Personal, Leadership Role, Past President: Chinese Society of Clinical Oncology (CSCO). J.F. Gainor: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Merck, Genentech/Roche, Takeda, Lilly, Moderna, AstraZeneca, Pfizer, Novartis, iTeos, Karyopharm, Silverback Therapeutics, GlydeBio, BeiGene;Financial Interests, Personal, Stocks/Shares, Immediate family member is an employee. Note: Ironwood Pharmaceuticals is not involved in any oncology drug development. It is focused on gastroenterology.: Ironwood Pharmaceuticals;Financial Interests, Personal and Institutional, InvitedSpeaker: Novartis;Financial Interests, Institutional, Invited Speaker: Genentech, Bristol Myers Squibb, Merck, AstraZeneca, Moderna, Jounce, Alexo. X. Zhang: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb;Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb. J. Sylvester: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb;Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb. S. Li: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb;Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb. J.C. Yang: Financial Interests, Institutional, Advisory Board: Astrazeneca, Boehringer Ingelheim, Daiichi Sankyo, Amgen, Novartis, Bayer, GSK, Takeda Oncology, Puma Pharmaceuticals, Ono Pharmaceuticals, Merck Serono, MSD, Pfizer, Eli Lilly, Roche/Genentech, Janssen;Financial Interests, Institutional, Invited Speaker: Astrazeneca, Boehringer Ingelheim, Novartis, Astrazeneca, MSD, Ipsen, Takeda Oncology;Financial Interests, Personal, Advisory Board: Yuhan Pharmaceuticals;Financial Interests, Personal, Invited Speaker: Dizal Pharmaceutical, Novartis, Numab, Merck, Daiichi Sankyo, Eli Lilly, Bayer, Janssen;Non-Financial Interests, Personal, Leadership Role, Board of Director: IASLC;Non-Financial Interests, Personal, Member: ASCO. All other authors have declared no conflicts of interest. Copyright © 2022

3.
Biochip Journal ; : 9, 2021.
Article in English | Web of Science | ID: covidwho-1163178

ABSTRACT

Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleoprotein (NP) were purified from pig serum through two steps: (1) isolation of anti-NP IgG antibodies using magnetic beads with immobilized human SARS-CoV-2 NP and (2) filtration of anti-spike protein (SP) IgG antibodies using magnetic beads with immobilized human SARS-CoV SP. The enhanced specificity of the purified antibodies to the NP of SARS-CoV-2 was demonstrated using an immunoassay with anti-NP IgG antibodies after the isolation and filtration steps. The binding constants (K-d) of the purified anti-NP IgG antibodies to the NP of SARS-CoV-2 and the SP of SARS-CoV were estimated using a surface plasmon resonance biosensor (SPR). A competitive assay using the two-step purified anti-NP IgG antibodies from pig serum demonstrated (a) the detection of SARS-CoV-2 in viral fluid and (b) the discrimination of SARS-CoV-2 from SARS-CoV, MERS-CoV, and CoV strain 229E in viral fluids.

4.
Journal of the Korean Academy of Fundamentals of Nursing ; 27(4):428-437, 2020.
Article in Korean | Scopus | ID: covidwho-1016402

ABSTRACT

Purpose: Coronavirus Disease 2019 (COVID-19), an emerging infectious disease introduced in South Korea in 2020. Medically inclined college students are more susceptible to be infected by the virus. The purpose of this study was to investigate factors influencing preventive behavior against COVID-19 among medically inclined college students. Methods: This is a cross-sectional study using a questionnaire survey. Data were collected from 400 medically inclined college students from four colleges of medice. Independent t-test, one-way ANOVA, Pearson correlation coefficients and multiple regression analysis were conducted to analysis the data. Results: The study subjects had high knowledge and optimism related to COVID-19. Preventive behavior against COVID-19 was affected mostly by attitude (β=.32, p<.001). Such behavior was also high in relation to knowledge (β=.17, p<.001), and nursing students (β=.15, p=.002). Conclusion: Infection prevention education for medically inclined college students mainly focuses on knowledge transfer. Infection preventive education programs aimed at improving COVID-19 optimistic attitudes and knowledge are helpful for these students to maintain appropriate preventive practices. The confirmation of the importance of optimistic attitudes and risk perception toward infectious diseases through this study can provide insight into infection prevention education programs to improve practice to wards new epidemic prevention behaviors. © 2020 Korean Academy of Fundamentals of Nursing.

5.
J Hosp Infect ; 106(3): 570-576, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-723894

ABSTRACT

BACKGROUND: Identifying the extent of environmental contamination of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential for infection control and prevention. The extent of environmental contamination has not been fully investigated in the context of severe coronavirus disease (COVID-19) patients. AIM: To investigate environmental SARS-CoV-2 contamination in the isolation rooms of severe COVID-19 patients requiring mechanical ventilation or high-flow oxygen therapy. METHODS: Environmental swab samples and air samples were collected from the isolation rooms of three COVID-19 patients with severe pneumonia. Patients 1 and 2 received mechanical ventilation with a closed suction system, while patient 3 received high-flow oxygen therapy and non-invasive ventilation. Real-time reverse transcription-polymerase chain reaction (rRT-PCR) was used to detect SARS-CoV-2; viral cultures were performed for samples not negative on rRT-PCR. FINDINGS: Of the 48 swab samples collected in the rooms of patients 1 and 2, only samples from the outside surfaces of the endotracheal tubes tested positive for SARS-CoV-2 by rRT-PCR. However, in patient 3's room, 13 of the 28 environmental samples (fomites, fixed structures, and ventilation exit on the ceiling) showed positive results. Air samples were negative for SARS-CoV-2. Viable viruses were identified on the surface of the endotracheal tube of patient 1 and seven sites in patient 3's room. CONCLUSION: Environmental contamination of SARS-CoV-2 may be a route of viral transmission. However, it might be minimized when patients receive mechanical ventilation with a closed suction system. These findings can provide evidence for guidelines for the safe use of personal protective equipment.


Subject(s)
Coronavirus Infections/therapy , Decontamination/standards , Environmental Pollution/analysis , Hyperbaric Oxygenation/standards , Patients' Rooms/standards , Pneumonia, Viral/therapy , Pneumonia/therapy , Practice Guidelines as Topic , Respiration, Artificial/standards , Air Microbiology , COVID-19 , Humans , Pandemics
SELECTION OF CITATIONS
SEARCH DETAIL